-

Advanced HPLC Column Delivers Improved Separation Performance and Protein Identification in Comprehensive New Proteomics Workflow

The new Thermo Scientific µPAC Neo HPLC Column brings improved column-to-column reproducibility and better protein identification to proteomics researchers

MINNEAPOLIS--(BUSINESS WIRE)--ASMS 2022Thermo Fisher Scientific Inc., the world leader in serving science, is providing proteomics and biopharmaceutical research laboratories with a new micro-pillar array column as part of an end-to-end LC-MS workflow that will simplify complex bottom-up proteomics analyses.

The Thermo Scientific µPAC Neo HPLC Column will initially be available to pre-order exclusively with the Thermo Scientific Vanquish Neo UHPLC System and Thermo Scientific Orbitrap Mass Spectrometers, delivering a comprehensive, single-solution LC-MS workflow complete with a detailed startup protocol. This helps users accelerate their experimental setup with the reassurance of high-level performance across every component of the workflow.

The new column delivers exceptional separation performance over a wide range of flow rates, offering the ultra-high resolution needed to extract maximum information from complex samples. As a result, laboratories will be able to identify a greater number of proteins and peptides in their proteomics experiments. Manufactured using the same lithographic mask, each column is close to identical, providing better column-to-column consistency and extended product lifetime relative to packed-bed column alternatives. The reduced need for column changes and resultant increased system up-time means method development, validation and large-scale studies will be significantly more streamlined. Furthermore, exceptional ease-of-use is assured by a suite of additional features, including the Thermo Scientific NanoViper Fingertight Fittings that enable swift, reliable connections that reduce errors and the need for repeat analysis.

“Proteomics researchers are demanding ever-greater sample coverage and improved protein identification to effectively advance their research. At the same time, the requirement for multiple columns in such studies raises the issue of consistent performance — especially when using traditional packed-bed columns,” said Remco Swart, director of marketing, chromatography consumables, Thermo Fisher Scientific. “The Thermo Scientific µPAC Neo HPLC Column overcomes these challenges by pairing powerful separation capabilities with dependable column-to-column reproducibility. Cross-column data comparison is simplified, and confidence in interpreting results and drawing conclusions is restored.”

Thermo Fisher Scientific is showcasing the Thermo Scientific µPAC Neo HPLC Column during the 70th American Society for Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics, being held June 5-9, 2022 in Booth 400 at the Minneapolis Convention Center, Minneapolis, Minnesota and at the Hilton Minneapolis Grand Ballrooms E, F, G.

Karl Mechtler, head of Protein Chemistry Facility of The Research Institute of Molecular Pathology (IMP) and head of Mass Spectrometry at Vienna BioCenter Core Facility, Vienna, Austria, said, “In the field of LC-MS based proteomics, increases in sampling depth and proteome coverage have mainly been accomplished by rapid advances in mass spectrometer technology. The comprehensiveness and quality of data that can be generated do, however, also depend on the performance provided by nano liquid chromatography (nanoLC) separations. Proper selection of reversed-phase separation columns can be of paramount importance to provide the MS instrument with peptides at the highest possible concentration and separated at the highest possible resolution. With the micro pillar array column (µPAC) designed for universal use in bottom-up proteomics, we demonstrated the potential for single-shot proteomics workflows.”

For more information on the Thermo Fisher solutions exhibited at ASMS 2022, please visit www.thermofisher.com/ASMS.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Laura Bright
Thermo Fisher Scientific
+1 562-335-8318
laura.bright@thermofisher.com

Janice Foley
BioStrata
+1 617-823-5555
jfoley@biostratamarketing.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Summary
The Thermo Scientific µPAC Neo HPLC Column improves column-to-column reproducibility and better protein identification to proteomics researchers.
Release Versions

Contacts

Laura Bright
Thermo Fisher Scientific
+1 562-335-8318
laura.bright@thermofisher.com

Janice Foley
BioStrata
+1 617-823-5555
jfoley@biostratamarketing.com

More News From Thermo Fisher

Thermo Fisher Scientific Deepens Investment in Asia’s Biopharma Ecosystem with Expansion of Bioprocess Design Centers

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region’s rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India, and has expanded its existing Bioprocess Design Centers in Incheon, Korea and Singapore, further strengthening a strategic regional network desig...

Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of €2.1 billion aggregate principal amount (the “Offering”) of the following euro-denominated notes, which will be issued by Thermo Fisher Scientific (Finance I) B.V., its indirect, wholly-owned finance subsidiary: €1,000,000,000 aggregate principal amount of its floating rate senior notes due 2027 (the “floating rate notes”) at the issue price of 100.000%...

Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients who may be eligible for treatment with HYRNUO™ (sevabertinib), a new HER2-directed therapy developed and commercialized by Bayer. The test enables clinicians and pathologists to identify non-small cell lung cancer (NSCLC) tumors wi...
Back to Newsroom